




#KeepYourThyroid #DesignedToPredictBenign

The Thyroid Genetic Classifier to safely forgo unnecessary diagnostic thyroid surgery for indeterminate cytology

Up to 20% of thyroid nodule FNA biopsies are reported as indeterminate (Bethesda III/IV) following cytological examination. These nodules are managed through diagnostic surgery which is the standard approach. After surgery, up to 75% of these nodules are determined to be benign.¹ ThyroidPrint® reclassifies nodules as either benign or suspicious of malignancy, aiding decision-making, avoiding patients to undergo unnecessary surgeries, and reducing healthcare costs.

ThyroidPrint® clinical pathway in case of thyroid nodule detection

ThyroidPrint® accurately classifies indeterminate thyroid nodules with 95% NPV^{2,3}




ThyroidPrint® Clinical Utility Study reduces unnecessary surgery by 67%⁴

Without ThyroidPrint®



With ThyroidPrint®



Idylla™ ThyroidPrint® Assay**

First-in-class cartridge-based Assay
for indeterminate thyroid nodules
For Research Use Only, assay currently under development

Idylla™ ThyroidPrint® Assay**



qPCR of 10 genes
in a diagnostic kit

Proprietary
algorithm analysis

ThyroidPrint Score
Reported as either 'High' or 'Low'



Tumor Inflammatory microenvironment Genes + Tumor Epithelial Genes + Stabilizing Genes



Unique sample-to-insight seamless workflow



Scan
Sample & Cartridge



Insert Sample
in the Cartridge



Insert Cartridge in the Idylla™ Platform
and obtain the result within 3 hours

- (1) Haugen et al., 2015 American Thyroid Association Management guidelines for adult patients. *Thyroid*, 2016
- (2) Gonzalez et al., A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study. *Thyroid*, 2017
- (3) Zafereo et al., A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. *Thyroid*, 2020
- (4) Olmos et al., ThyroidPrint®: clinical utility for indeterminate thyroid cytology. *End Rel Cancer*, 2023

thyroidprint.com



GENEPRODX
Transforming Precision Medicine



Biocartis NV
Generaal De Wittelaan 11B
2800 Mechelen - Belgium
+32 15 632 888

Follow us on [f](#) [t](#) [in](#)

www.biocartis.com
customerservice@biocartis.com

*ThyroidPrint® LDT currently available as a Laboratory Developed Test in GeneproDx® CAP accredited laboratory in Santiago de Chile (Chile).

**Idylla™ ThyroidPrint® is currently under development and planned to be released as an assay for Research Use Only, not for use in diagnostic procedures. The Idylla™ ThyroidPrint® Assay is developed by GeneproDX and distributed by Biocartis. © Biocartis NV, August 2023. All rights reserved.

IOUS.FL060.EN.R1/08/2023

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx